Betting on Sabirnetug: A Binary Long into Acumen Ahead of Late-2026 Readout
Acumen Pharmaceuticals (ABOS) is a clinical-stage Alzheimer’s developer with sabirnetug (ACU193) in a Phase 2 trial. Topline results from ALTITUDE-AD are expected in late 2026. With $128.4M in cash, a market cap of ~$157.5M, depressed technicals, and a relatively small float, the stock is a defined-risk way to play a positive Phase 2 readout. This …